Novartis Blood-Pressure Drug Rasilez to Carry Warning - Wall Street Journal PDF Print
Wall Street Journal
Data suggest a risk of adverse outcomes in such patients, including hypotension, stroke and changes in renal function, including acute renal failure, the EMA said. In addition, the EMA recommended that aliskiren's prescribing label carry a warning ...
Novartis to revise product information in the European Union for high blood ... Reuters
European Medicines Agency Recommends New Contraindications and Warnings for

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.